Novo Nordisk Continues DKK 15 Billion Share Repurchase Programme

Novo Nordisk A/S has provided an update on its ongoing share repurchase initiative, which is part of a broader capital return strategy valued at up to DKK 15 billion. The programme is being executed over a 12-month period that officially commenced on February 4, 2026. These transactions are conducted in strict accordance with 'Safe Harbour' rules and the European Union’s Market Abuse Regulation (MAR). The primary objective of this initiative is to optimize the company's capital structure while returning value to its shareholders. Market analysts view the buyback as a bullish signal, reflecting management's confidence in the company's long-term valuation. By reducing the overall share supply, the programme typically supports the stock price and reinforces Novo Nordisk's position within the pharmaceutical sector.